Impact of academic medical center access on outcomes in multiple myeloma
Abstract Treatment at academic cancer centers (ACs) is associated with improved survival across hematologic malignancies, though the benefit in multiple myeloma (MM) has not been examined. This study aims to evaluate survival outcomes at Commission on Cancer accredited ACs compared to non‐academic centers (NACs) for patients receiving MM‐directed therapy. The National Cancer Database (NCDB) was used to identify demographics and overall survival (OS) of MM patients diagnosed from 2004 to 2017 and to compare outcomes by facility type. Survival analysis was repeated in a propensity score matched cohort, with NACs matched 1:1 to ACs by age, race, comorbidity score, insurance, year of diagnosis, distance traveled, and income. Of 163 375 MM patients, 44.5% were treated at ACs. Patients at ACs were more likely to receive MM‐directed therapy compared to NACs (81% vs. 73%, p < .001). For patients receiving treatment, median OS at ACs was 71.3 months versus 41.2 months at NACs ( p < .001). When adjusted for baseline demographics, patients treated at ACs had reduced mortality; hazard ratio (HR) 0.79 (95% CI 0.78–0.81, p < .001). The propensity score matched cohort maintained this survival benefit with a median OS of 59.9 months at ACs versus 37.0 months at NACs ( p < .001), HR of 0.66 (95% CI 0.64–0.67, p < .001). ACs treated younger patients with fewer comorbidities and were more likely to treat racial minorities and patients with Medicaid or private insurance, and the uninsured. In this analysis, MM patients treated at ACs have significantly improved survival. While potentially related to access to specialized care, socioeconomic factors that drive facility selection may also contribute..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:98 |
|---|---|
| Enthalten in: |
American Journal of Hematology - 98(2023), 1, Seite 41-48 |
| Beteiligte Personen: |
Vardell, Victoria A. [VerfasserIn] |
|---|
| BKL: |
|---|
| Anmerkungen: |
© 2023 Wiley Periodicals LLC. |
|---|
| Umfang: |
8 |
|---|
| doi: |
10.1002/ajh.26759 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
WLY001126423 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | WLY001126423 | ||
| 003 | DE-627 | ||
| 005 | 20230307101149.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230210s2023 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1002/ajh.26759 |2 doi | |
| 028 | 5 | 2 | |a AJH_AJH26759.xml |
| 035 | |a (DE-627)WLY001126423 | ||
| 035 | |a (WILEY)AJH26759 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 084 | |a 44.86 |2 bkl | ||
| 100 | 1 | |a Vardell, Victoria A. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Impact of academic medical center access on outcomes in multiple myeloma |
| 264 | 1 | |c 2023 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © 2023 Wiley Periodicals LLC. | ||
| 520 | |a Abstract Treatment at academic cancer centers (ACs) is associated with improved survival across hematologic malignancies, though the benefit in multiple myeloma (MM) has not been examined. This study aims to evaluate survival outcomes at Commission on Cancer accredited ACs compared to non‐academic centers (NACs) for patients receiving MM‐directed therapy. The National Cancer Database (NCDB) was used to identify demographics and overall survival (OS) of MM patients diagnosed from 2004 to 2017 and to compare outcomes by facility type. Survival analysis was repeated in a propensity score matched cohort, with NACs matched 1:1 to ACs by age, race, comorbidity score, insurance, year of diagnosis, distance traveled, and income. Of 163 375 MM patients, 44.5% were treated at ACs. Patients at ACs were more likely to receive MM‐directed therapy compared to NACs (81% vs. 73%, p < .001). For patients receiving treatment, median OS at ACs was 71.3 months versus 41.2 months at NACs ( p < .001). When adjusted for baseline demographics, patients treated at ACs had reduced mortality; hazard ratio (HR) 0.79 (95% CI 0.78–0.81, p < .001). The propensity score matched cohort maintained this survival benefit with a median OS of 59.9 months at ACs versus 37.0 months at NACs ( p < .001), HR of 0.66 (95% CI 0.64–0.67, p < .001). ACs treated younger patients with fewer comorbidities and were more likely to treat racial minorities and patients with Medicaid or private insurance, and the uninsured. In this analysis, MM patients treated at ACs have significantly improved survival. While potentially related to access to specialized care, socioeconomic factors that drive facility selection may also contribute. | ||
| 700 | 1 | |a Ermann, Daniel A. |4 aut | |
| 700 | 1 | |a Tantravahi, Srinivas K. |4 aut | |
| 700 | 1 | |a Haaland, Benjamin |4 aut | |
| 700 | 1 | |a McClune, Brian |4 aut | |
| 700 | 1 | |a Godara, Amandeep |4 aut | |
| 700 | 1 | |a Mohyuddin, Ghulam Rehman |4 aut | |
| 700 | 1 | |a Sborov, Douglas W. |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t American Journal of Hematology |g 98(2023), 1, Seite 41-48 |w (DE-627)WLY001111442 |x 10968652 |7 nnns |
| 773 | 1 | 8 | |g volume:98 |g year:2023 |g number:1 |g pages:41-48 |g extent:8 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_WLY | ||
| 936 | b | k | |a 44.86 |q ASE |
| 951 | |a AR | ||
| 952 | |d 98 |j 2023 |e 1 |h 41-48 |g 8 | ||